STORM Therapeutics to Host First RNA Epigenetics Conference in Cambridge UK

CAMBRIDGE, England: STORM Therapeutics, the drug discovery company focused on the discovery of small molecule therapeutics modulating RNA epigenetics, today announced that it will be hosting an international conference focused on the emerging field of RNA epigenetics.

The Conference, entitled RNA epigenetics in human disease is the first of its kind and will take place on 17-20 September 2019 at St Catharine's College, Cambridge, UK.

RNA epigenetics is an exciting, emerging, innovative area of biology and STORM is the first company to explore the therapeutic potential of the field.

Founded in 2015, STORM is a University of Cambridge spin-out translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. STORM is tackling disease through modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases.

The conference will host an incredible line up of international speakers and experts covering aspects of RNA epigenetics. Speakers include

Robert Copeland - President, Chief Scientific Officer & Co-founder - Accent Therapeutics
Richard Gregory - Principal Investigator - Boston Children's Hospital
Chuan He - Professor - The University of Chicago
Samie Jaffrey - Professor - Weill Medical College, Cornell University
Tony Kouzarides - Gurdon Institute and STORM Therapeutics
Eric Miska - Gurdon Institute and STORM Therapeutics
Gerhard Muller - Chief Scientific Officer - Gotham Therapeutics
Oliver Rausch - Chief Scientific Officer - STORM Therapeutics
(PRN | 5 months ago)

Like This Article?
STORM Therapeutics to Host First RNA Epigenetics Conference in Cambridge UK